Cancer genome sequencing efforts reveal that in addition to mutations in growth-promoting signaling pathways such as in EGFR and KRAS, chromatin-modifying enzymes and epigenetic regulators such as KMT2D, ARID1A, and TET2 are also frequent targets of genetic alterations (Kandoth et al., 2013). This evidence concerns the gene KRAS and cancer.